America's Best Nonprofits
  1. Home
  2. Medical Research
  3. Atlanta, GA
  4. Odylia Therapeutics

Odylia Therapeutics

Odylia Therapeutics has an America's Best Score of 54 out of 100, based on its 2025 Form 990, below the 60-point bar to be ranked.

  • Atlanta, GA
  • Tax-exempt since 2018
  • EIN: 82-2120760
odylia.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
54OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

Odylia Therapeutics is a 501(c)(3) organization, classified under Medical Research (NTEE H41). Contributions are tax-deductible.

830 Glenwood Ave Se Ste 510 Pmb 32, Atlanta, GA 30316-2176

Among the 12 scored medical research organizations in Atlanta, Odylia Therapeutics holds 7 months of operating reserves (peer median 7.8 months), runs a typical yearly deficit of 11.4% (peers: deficit of 3.0%), and has grown spending 17.5% a year (peers: grown spending 13.1% a year).

In fiscal year 2025 it reported $1,523,364 in revenue and $1,406,969 in expenses, with contributions making up 59.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Odylia utilizes a unique, non-profit model to develop and advance therapeutics for people with rare diseases, changing the way treatments are brought from the lab to the clinic.

Main program · fiscal year 2025

  • Odylia's two primary initiatives are the odylia pipeline and brydge solutions. The pipeline includes the rpgrip1, ush1c, and nphp1 gene therapy programs. Significant accomplishments included a successful fda pre-ind meeting and preclinical development activities for the rpgrip1 program, clinical candidate selection and delivery optimization for the ush1c program, and initial vector design and test… Read more

    Odylia's two primary initiatives are the odylia pipeline and brydge solutions. The pipeline includes the rpgrip1, ush1c, and nphp1 gene therapy programs. Significant accomplishments included a successful fda pre-ind meeting and preclinical development activities for the rpgrip1 program, clinical candidate selection and delivery optimization for the ush1c program, and initial vector design and testing for the nphp1 program. Brydge solutions accelerates the development of treatments for rare diseases through strategic partnerships with patient advocacy organizations, disease foundations, and rare disease families. In 2025, the program established five new partnerships with save sight now, med13l foundation, upstream genes, dlg4 shine syndrome foundation, and pbd project.

    $1,197,948 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 85¢ went to programs, 8¢ to management and 7¢ to fundraising.

  • Programs $1,197,948
  • Management $106,241
  • Fundraising $102,780

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score54 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves7.0 mo; 5.4 mo in cash4.9 / 25
Financial balance (median margin)−11.4%10 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+17.5% / yr15 / 15
Track record8 years3.2 / 10
Debt load52.9% of assets1.4 / 10
Total54.5 → 54
Spending on programs
Not scored; America's Best needs 65%+
85%Meets

Compared with Atlanta peers

MeasureThis organizationPeer median
Operating reserves7.0 mo7.8 mo
Typical margin−11.4%−3.0%
Spending growth+17.5% / yr+13.1% / yr
Debt load52.9%17.8%

Peers: the 12 Atlanta medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$1,523,364Fiscal year 20252022: $1,098,40120222023: $570,77320232024: $482,04720242025: $1,523,3642025
Expenses$1,406,969Fiscal year 20252022: $866,47320222023: $867,23620232024: $699,40520242025: $1,406,9692025
Total assets$1,741,781Fiscal year 20252022: $10,021,65120222023: $9,688,64420232024: $1,594,79520242025: $1,741,7812025
Total liabilities$921,012Fiscal year 20252022: $95,75720222023: $41,33620232024: $907,23920242025: $921,0122025
Fiscal year ending December 2025
Revenue$1,523,364
Expenses$1,406,969
Net income$116,395
Net assets$820,769

Notable sources of revenue

Percent of total revenue
Contributions$898,455
Program services$609,083
Investment income$15,826
Other (net)$0

Assets / debt

Total assets$1,741,781
Total liabilities$921,012
Net assets$820,769

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$482,047
Expenses$699,405
Net income−$217,358
Net assets$687,556

Notable sources of revenue

Percent of total revenue
Contributions$291,256
Program services$144,417
Investment income$46,374
Other (net)$0

Assets / debt

Total assets$1,594,795
Total liabilities$907,239
Net assets$687,556

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$570,773
Expenses$867,236
Net income−$296,463
Net assets$9,647,308

Notable sources of revenue

Percent of total revenue
Contributions$289,283
Program services$241,089
Investment income$40,401
Other (net)$0

Assets / debt

Total assets$9,688,644
Total liabilities$41,336
Net assets$9,647,308

Compensation

Officers and key employees$230,695
Share of expenses26.6%
Fiscal year ending December 2022
Revenue$1,098,401
Expenses$866,473
Net income$231,928
Net assets$9,925,894

Notable sources of revenue

Percent of total revenue
Contributions$976,484
Program services$107,361
Investment income$14,556
Other (net)$0

Assets / debt

Total assets$10,021,651
Total liabilities$95,757
Net assets$9,925,894

Compensation

Officers and key employees$210,664
Share of expenses24.3%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?